Related references
Note: Only part of the references are listed.Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab
Dawn Odom et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2011)
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study
Federica Andreis et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Ohidul Siddiqui et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Fairooz F. Kabbinavar et al.
ONCOLOGIST (2008)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer
C. Byrne et al.
EJSO (2007)
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
S. Siena et al.
BRITISH JOURNAL OF CANCER (2007)
Health utilities using the EQ-5D in studies of cancer
A. Simon Pickard et al.
PHARMACOECONOMICS (2007)
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Anna Liza C. Agero et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population
S Petrou et al.
HEALTH ECONOMICS (2005)
Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30
PFM Krabbe et al.
QUALITY OF LIFE RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
